- Multimodal artificial intelligence models from baseline histopathology to predict prognosis in HR+HER2- early breast cancer: Subgroup analysis (Presenter: Daniel Kates-Harbeck)
- Multiomic factor analysisfor pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial (Presenter: Monika Graeser)
- Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV (Presenter: Nadia Harbeck)
